LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sysmex Highlights Innovations in Flow Cytometry, Urinalysis and Hematology

By LabMedica International staff writers
Posted on 02 Aug 2018
Print article
Image: The XW-100 CBC analyzer (Photo courtesy of Sysmex).
Image: The XW-100 CBC analyzer (Photo courtesy of Sysmex).
Sysmex (Kobe, Japan) celebrated its 50th anniversary at this year’s annual meeting of the American Association for Clinical Chemistry (AACC) and shared its plans to equip the clinical laboratory of the future with innovative solutions in flow cytometry, urinalysis and hematology. The AACC 2018 held July 29 – August 2 in Chicago, Illinois, USA, was attended by approximately 20,000 clinical laboratory professionals from more than 110 countries.

Sysmex offers clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems. The company is innovating across all of its diagnostic practices, including flow cytometry, urinalysis and hematology.

At AACC 2018, Sysmex showcased its first fully automated urine particle analyzer, which reduces the need for manual slide review and delivers first-pass accuracy and unprecedented workflow efficiency. Sysmex’s UN series consists of three analyzer modules and is the first fully configurable urinalysis solution to offer expanded parameters. In addition to being configurable to meet the needs of every laboratory, Sysmex’s solution will allow laboratorians to focus more time on analyzing test results.

Visitors to the Sysmex booth were able to view the company’s new comprehensive flow cytometry system which is highly automated and features a broad portfolio of CyFlow anti-body reagents and the PS-10 sample preparation system with automated cell wash. The new product also includes the XF-1600 flow cytometer with multi-colored capability, high sample throughput and software solutions for the most difficult samples. Sysmex also displayed its FDA-cleared XN-20 complete blood count (CBC) analyzer, a complementary system to its XN-10.

Also on display at Sysmex’s booth at AACC was the automated GloCyte cell counter system, which provides an unprecedented detection level for automated cerebrospinal fluid (CSF) cell counts. Sysmex also showcased its first-of-its-kind XW-100, the world’s first CLIA-waived CBC analyzer that can provide three-part blood test results in as few as three minutes, allowing patients to get answers faster and their physicians to develop treatment plans more quickly.

“As we celebrate five decades of providing laboratories around the world with highly accurate, efficient and dependable diagnostic solutions, we are excited about what we have in store for the laboratory of the future,” said Ralph Taylor, chief executive officer of Sysmex America. “The path to better healthcare is through better testing and Sysmex is lighting the way.”

“Laboratories are facing growing staffing and reimbursement challenges,” said Andy Hay, chief operating officer of Sysmex America. “Sysmex is developing innovative solutions that increase efficiency and allow clinical laboratory professionals to do the work that both ignites their passion for diagnostics and leads to the greatest impact on patient care.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more